In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Bromazepam Drug Master File in Korea (Bromazepam KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Bromazepam. The MFDS reviews the Bromazepam KDMF as part of the drug registration process and uses the information provided in the Bromazepam KDMF to evaluate the safety and efficacy of the drug.
After submitting a Bromazepam KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Bromazepam API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Bromazepam suppliers with KDMF on PharmaCompass.